News & Events

≪ Back to All News & Events

October 12, 2010

Mid-Atlantic Bio Conference Reveals Companies Selected to Present at October Conference

Mid-Atlantic Bio Conference Reveals Companies Selected to Present at October Conference

WASHINGTON D.C. (October 12, 2010)—Mid-Atlantic Bio today announced a much anticipated line-up of companies selected to present at their upcoming 2010 Mid-Atlantic Bio Conference, being held October 27-29 at the North Bethesda Marriott Convention Center in Bethesda, Md. Dedicated to promoting the biotechnology industry in the Mid-Atlantic region, the conference is hosted collectively by the region’s most influential bioscience and investor associations, the Mid-Atlantic Venture Association (MAVA), the Tech Council of Maryland/MdBio (MdBio) and the Virginia Biotechnology Association (VaBIO).

Each year at Mid-Atlantic Bio, a limited number of life science companies are chosen to present before a sought-after audience that includes a variety of capital sources, from corporate business development professionals to venture capitalists, angel investors, and various other qualified financing sources along with important industry professionals, peer scientists, company leaders and potential strategic partners. Over the past seven years, more than 1,200 companies have participated in Mid-Atlantic Bio, with more than 100 of those as presenters on the program, resulting in hundreds of millions in private financings and corporate investments, M&A activities, strategic partnerships and industry collaborations.

This year’s conference features three tracks that will highlight the company presenters that were chosen including the Showcase track, Emerging Growth track and a newly added First Look/Fast Pitch track. The companies chosen specialize in medical devices, health care IT, diagnostics, drug development, pharmaceuticals, biotherapeutics, biopharmaceuticals, therapeutics and gene therapeutics.

“Hearing the scientific advances and business cases directly from some of the leading seasoned and newly formed enterprises adds richness to this conference that is extremely powerful,” says Julia Spicer, Executive Director of the Mid-Atlantic Venture Association (MAVA). “Showcasing companies at various stages of development encourages future innovation as well as connections that foster investment opportunities, collaboration and partnering and the sharing of best practices – all at the core of Mid-Atlantic Bio.”

To be selected for a speaking spot at the conference, companies went through a multi-phase application review and competitive selection process. Numerous companies applied and were judged against such criteria as scientific interest, technology innovation, stage of development, addressable market, or recent enterprise advances and milestones achieved.

The following companies were chosen to present within each track:

Showcase:

  • Argos Therapeutics of Durham, NC
  • Sucampo Pharmaceuticals, Inc. of Bethesda, MD
  • Supernus Pharmaceuticals of Rockville, MD
  • TetraLogic Pharmaceuticals of Malvern, PA
  • Zyngenia of Gaithersburg, MD

Emerging Growth:

  • AFrame Digital of Reston, VA
  • Ceres Nanosciences of Manassas, VA
  • CSA Medical of Baltimore, MD
  • Envisionier Medical Technologies, Inc. of Woodstock, GA
  • Functional Genetics of Gaithersburg, MD
  • NexGen Medical Systems, Inc. of Melbourne, FL
  • Noxilizer of Baltimore, MD
  • Plasmonix, Inc. of Baltimore, MD
  • Sequella Inc. of Rockville, MD
  • Sirnaomics, Inc. of Gaithersburg, MD
  • TAU Therapeutics of Charlottesville, VA

First Look/Fast Pitch:

  • Altammune, Inc. of Baltimore, MD
  • Audiodontics of Bethesda, MD
  • Creatv MicroTech, Inc. of Potomac, MD
  • CW Optics, Inc. of Seaford, VA
  • EncephRx of Baltimore, MD
  • RAFAGEN, Inc. of Rockville, MD
  • Seguro Surgical of Columbia, MD
  • Seneb Biosciences of Doylestown, PA
  • Techulon of Blacksburg, VA

Amita Shukla, Principal of New Enterprise Associates and member of the 2010 Selection Committee, notes that “The Selection Committee, with input from a qualified cross-section of industry and investor sources, is pleased to present a line-up of multi-staged companies this year, each with a unique opportunity to explore.”

Now in its seventh year, Mid-Atlantic Bio is the only globally-focused, yet regionally-based, event to combine components of a bioscience industry convention with an investor conference under one roof. More than 800 national and international industry leaders, government representatives, executives, researchers, investors, entrepreneurs, and professional services firms will gather to promote networking, business expansion, and technical-knowledge sharing. Home to industry-critical regulatory and research agencies; federal policymaking; and business and scientific centers of excellence, the Mid-Atlantic is a unique center for the global bioscience industry.

Conference Sessions:
Designed to be a platform that brings together science, company builders, commercial interests and collaborators, capital sources, and federal and regulatory thought-leaders, the 2010 program includes a variety of important industry topics—ranging from the latest in policy and regulatory matters, business and financing opportunities, and CEO War Stories to advances in science and technology—and showcases exciting companies from the biosciences field. A few of the highlighted sessions include:

  • Building a Workforce Culture Around Commercialization
  • Corporate Venture and Early Stage Partnerships
  • Regulation and Reimbursement in a World of Changing Policies, Laws and Procedures
  • New Science Technologies: Regional Successes
  • An Insider’s View on Washington
  • Synthetic Biology – Applications and Implications
  • Accessing the Regulatory Risk: Your Path to Approval
  • CEO War Stories: A Roundtable

Plenary presentations by John Castellani, President and CEO of PhRMA, John F. Crowley, JD, MBA, Chairman and CEO of Amicus Therapeutics; Frederick Frank, Vice Chairman, Peter J. Solomon Company; James Greenwood, President and CEO of BIO; Martine A. Rothblatt, PhD, JD, MBA, Chairman and CEO of United Therapeutics Corporation; Joshua M. Sharfstein, MD, Principal Deputy Commissioner, U.S. Food and Drug Administration; and H. Thomas Watkins, President and CEO, Human Genome Sciences

BioMatch:
Mid-Atlantic Bio’s signature networking program, BioMatch, is designed specifically for the life sciences and biotech industries, and provides registered attendees access to advanced partnering software that facilitates personalized, one-on-one meetings between the leading bioscience organizations and industry leaders.

Partial List of Conference Sponsors:
Human Genome Sciences, Maryland Biotechnology Center, MedImmune, Biotechnology Industry Organization, Cooley LLP, Grand Thornton LLP, Hogan Lovells, Wilson Sonsini Goodrich & Rosati, BioMed Realty Trust, Inc., BDO, Alexandria Real Estate Equities, Inc., Janelia
Farms Research Campus of Howard Hughes Medical Institute, NIH Federal Credit Union, George Mason University, Virginia Tech, James Madison University, Broad Oak Partners, H.I.G. BioVentures, CIT Gap Funds, Intersouth Partners, New Enterprises Associates, Oxford Finance, TEDCO, Third Security, LLC. See the complete listing of sponsors.

ABOUT MID-ATLANTIC BIO
The Mid-Atlantic Bio Conference, scheduled October 27-29, 2010, in Bethesda, Maryland, is co-hosted by the Tech Council of Maryland/MdBio (TCM/MdBio), the Mid-Atlantic Venture Association (MAVA), and the Virginia Biotechnology Association (VaBIO). Mid-Atlantic Bio benefits from broad regional support from the investor and greater business communities, academic institutions, government agencies, and partnering regional associations. For more information, or to register or sponsor, please visit www.midatlanticbio.org. You may read the article here.

> Click here to Download PDF